ARS Pharmaceuticals, Inc. (SPRY) P/E Ratio History
Deep ValueTrading at -2.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2024–2024
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, ARS Pharmaceuticals, Inc. (SPRY) trades at a price-to-earnings ratio of -2.3x, with a stock price of $4.07 and trailing twelve-month earnings per share of $-2.17.
The current P/E is 102% below its 5-year average of 150.7x. Over the past five years, SPRY's P/E has ranged from a low of 150.7x to a high of 150.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, SPRY trades at a 110% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, SPRY trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SPRY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SPRY Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SPRY P/E vs Peers
Drug Delivery Technology Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 16.2Lowest | - | -26% | |
| $13B | 42.9 | 1.87Best | -25% | |
| $464B | 110.9 | - | -1% | |
| $4B | 45.4 | - | -72% | |
| $108B | 23.5 | - | +49% | |
| $53B | 31.6 | - | +325%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SPRY Historical P/E Data (2024–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | - | $10.55 | $0.07 | 150.7x | +0% |
Average P/E for displayed period: 150.7x
SPRY Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SPRY — Frequently Asked Questions
Quick answers to the most common questions about buying SPRY stock.
What is SPRY's P/E ratio?
ARS Pharmaceuticals, Inc. (SPRY) trailing twelve-month P/E ratio is -2.3x, based on TTM diluted EPS of $-2.17. The 5-year average P/E is 150.7x and the historical range spans 150.7x to 150.7x.
Is SPRY stock overvalued or undervalued?
SPRY trades at -2.3x P/E, below its 5-year average of 150.7x. At the 0th percentile of its historical range (150.7x–150.7x), the stock is priced at a discount to its own history.
Is SPRY stock expensive?
No, SPRY is not expensive on a historical basis. The current P/E of -2.3x is below the 5-year average of 150.7x and sits at the 0th percentile of its valuation range.
What is SPRY's historical P/E range?
Over the past 5 years, SPRY's P/E ratio has ranged from 150.7x to 150.7x, with a median of 150.7x and an average of 150.7x. The current P/E of -2.3x places the stock at the 0th percentile of this range. Full historical data spans 2024–2024.
How does SPRY's P/E compare to the S&P 500?
SPRY trades at -2.3x P/E versus the S&P 500 median of 24.5x. The 109% discount to the market suggests lower growth expectations or perceived higher risk.
How does SPRY's valuation compare to Healthcare peers?
ARS Pharmaceuticals, Inc. P/E of -2.3x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SPRY's PEG ratio?
SPRY PEG ratio is N/A, based on a P/E of -2.3x and EPS growth of -2327.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SPRY's earnings yield?
SPRY earnings yield is N/A, the inverse of its -2.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.